Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Кардиологические аспекты сахарного диабета 2 типа

СПИСОК ЛИТЕРАТУРЫ

  1. http://www.idf.org/diabetesatlas.
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017. Т. 20. № 1. С. 13–41.
  3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016. № 2. С. 104–112.
  4. American Diabetes A. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018. 41(5): 917–928.
  5. Hogan P., Dall T., Nikolov P., American Diabetes A. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003. 26(3): 917–932.
  6. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Колбин A.C., Рафальский В.В., Чеберда А.Е., et al. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2017. Т. 20. № 6. С. 403–419.
  7. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001. 24(4): 683–689.
  8. Карпов Ю.А., Кухарчук В.В., Лякишев А.А., Лупанов В.П., Панченко Е.П., Комаров А.Л., et al. Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации. 2013.
  9. Сергиенко И.В., Аншелес А.А., Кухарчук В.В. Атеросклероз и дислипидемии: современные аспекты патогенеза, диагностики и лечения. Москва. 2017.
  10. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004. 364(9438): 937–952.
  11. Калашникова М.Ф., Сунцов Ю.И., Белоусов Д.Ю., Кантемирова М.А. Анализ эпидемиологических показателей сахарного диабета 2 типа среди взрослого населения города Москвы. Сахарный диабет. 2014. Т. 17. № 3. С. 5–16.
  12. Толпыгина С.Н., Марцевич С.Ю., Деев А.Д. Влияние сопутствующих заболеваний на отдаленный прогноз пациентов с хронической ишемический болезнью сердца по данным регистра ПРОГНОЗ-ИБС. Рациональная фармакотерапия в кардиологии. 2015. Т. 11. № 6. С. 571–576.
  13. Emerging Risk Factors C., Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010. 375(9733): 2215–2222.
  14. Diabetes C., Complications Trial Research G., Nathan D.M., Genuth S., Lachin J., Cleary P., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329(14): 977–986.
  15. White N.H., Sun W., Cleary P.A., Tamborlane W.V., Danis R.P., Hainsworth D.P., et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010. 59(5): 1244–1253.
  16. Su G., Mi S.H., Tao H., Li Z., Yang H.X., Zheng H., et al. Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. 2013. 36(4): 1026–1032.
  17. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998. 317(7160): 703–713.
  18. Emerging Risk Factors C., Di Angelantonio E., Gao P., Khan H., Butterworth A.S., Wormser D., et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014. 311(12): 1225–1233.
  19. Su G., Mi S., Tao H., Li Z., Yang H., Zheng H., et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011. 10: 19.
  20. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Сахарный диабет. 2017. Т. 20. № 1S. С. 1–112.
  21. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Клинические рекомендации РКО, НОНР РАЭ, РМОАГ, НОА, РНМОТ. Российский кардиологический журнал. 2014. Т. 8. № 112. С. 7–37.
  22. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013. 34(28): 2159–2219.
  23. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016. 37(29): 2315–2381.
  24. Pastromas S., Terzi A.B., Tousoulis D., Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol. 2008. 126(1): 3–12.
  25. Sniderman A.D., Lamarche B., Tilley J., Seccombe D., Frohlich J. Hypertriglyceridemic hyperapoB in type 2 diabetes. Diabetes Care. 2002. 25(3): 579–582.
  26. Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Type 2 diabetes as a «coronary heart disease equivalent»: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005. 28(12): 2901–2907.
  27. Scott R., O’Brien R., Fulcher G., Pardy C., D’Emden M., Tse D., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009. 32(3): 493–498.
  28. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007. 357(13): 1301–1310.
  29. Krauss R.M., Siri P.W. Dyslipidemia in type 2 diabetes. Med Clin North Am. 2004. 88(4): 897–909, x.
  30. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008. 28(7): 1225–1236.
  31. Solano M.P., Goldberg R.B. Management of dyslipidemia in diabetes. Cardiol Rev. 2006. 14(3): 125–135.
  32. Yang H., Fogo A.B., Kon V. Kidneys: key modulators of high-density lipoprotein levels and function. Curr Opin Nephrol Hypertens. 2016. 25(3): 174–179.
  33. Figueira M.F., Castiglione R.C., de Lemos Barbosa C.M., Ornellas F.M., da Silva Feltran G., Morales M.M., et al. Diabetic rats present higher urinary loss of proteins and lower renal expression of megalin, cubilin, ClC-5, and CFTR. Physiol Rep. 2017. 5(13).
  34. Sniderman A.D., Scantlebury T., Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001. 135(6): 447–459.
  35. Krentz A.J. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003. 5 Suppl 1: S19–27.
  36. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010. 45(10): 907–914.
  37. Paneni F., Beckman J.A., Creager M.A., Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013. 34(31): 2436–2443.
  38. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001. 88(2): E14–22.
  39. Massi-Benedetti M., Board C.-A. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia. 2002. 45(7): S1–4.
  40. Sasmaz H., Yilmaz M.B. Coronary collaterals in obese patients: impact of metabolic syndrome. Angiology. 2009. 60(2): 164–168.
  41. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VI пересмотр. Атеросклероз и дислипидемии. 2017. Т. 3. № 28. С. 5–23.
  42. Сергиенко И.В., Шестакова М.В., Бойцов С.А., Кухарчук В.В., Затейщиков Д.А., Ежов М.В., с соавт. Экстремальная категория риска в системе стратификации сердечно-сосудистых осложнений. Консенсус совета экспертов. Атеросклероз и дислипидемии. 2018. № 4 (31).
  43. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol. 2014. 171(3): 309–325.
  44. de Boer I.H., Bakris G., Cannon C.P. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018. 319(13): 1319–1320.
  45. Barter P.J., Waters D.D. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol. 2018.
  46. Brignole M., Auricchio A., Baron-Esquivias G., Bordachar P., Boriani G., Breithardt O.A., et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013. 34(29): 2281–2329.
  47. Hernandez-Ojeda J., Roman-Pintos L.M., Rodriguez-Carrizalez A.D., Troyo-Sanroman R., Cardona-Munoz E.G., Alatorre-Carranza Mdel P., et al. Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study. Diabetes Metab Syndr Obes. 2014. 7: 401–407.
  48. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003. 361(9364): 1149–1158.
  49. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004. 364(9435): 685–696.
  50. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002. 360(9326): 7–22.
  51. Cholesterol Treatment Trialists C., Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010. 376(9753): 1670–1681.
  52. Haffner S.M., American Diabetes A. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004. 27 Suppl 1: S68–71.
  53. Sadowitz B., Maier K.G., Gahtan V. Basic science review: Statin therapy-Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010. 44(4): 241–251.
  54. Correale M., Abruzzese S., Greco C.A., Concilio M., Biase M.D., Brunetti N.D. Pleiotropic effects of statin in therapy in heart failure: a review. Curr Vasc Pharmacol. 2014. 12(6): 873–884.
  55. Robinson J.G., Stone N.J. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015. 36(31): 2110–2118.
  56. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003. 92(2): 152–160.
  57. Bener A., Dogan M., Barakat L., Al-Hamaq A.O. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome. J Prim Care Community Health. 2014. 5(3): 180–187.
  58. Сергиенко И.В. Ингибирование всасывания холестерина в энтероцитах. Атеросклероз и дислипидемии. 2012. (1): 37–47.
  59. Morrone D., Weintraub W.S., Toth P.P., Hanson M.E., Lowe R.S., Lin J., et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012. 223(2): 251–261.
  60. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015. 372(25): 2387–2397.
  61. Warraich H.J., Wong N.D., Rana J.S. Role for combination therapy in diabetic dyslipidemia. Curr Cardiol Rep. 2015. 17(5): 32.
  62. Balendiran G.K., Rath N., Kotheimer A., Miller C., Zeller M., Rath N.P. Biomolecular chemistry of isopropyl fibrates. J Pharm Sci. 2012. 101(4): 1555–1569.
  63. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999. 341(6): 410–418.
  64. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., 3rd, Leiter L.A., Linz P., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010. 362(17): 1563–1574.
  65. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005. 366(9500): 1849–1861.
  66. Аметов А.С., Прудникова М.А. Нелипидные эффекты фенофибрата: акцент на сахарный диабет. Сахарный диабет. 2014. (4): 43–50.
  67. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood. 1999. 93(9): 2991–2998.
  68. Salehi E., Khazaei M., Rashidi B. Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats. Gen Physiol Biophys. 2012. 31(3): 255–260.
  69. Chew E.Y., Davis M.D., Danis R.P., Lovato J.F., Perdue L.H., Greven C., et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014. 121(12): 2443–2451.
  70. Buckley L.F., Dixon D.L., Wohlford G.F.t., Wijesinghe D.S., Baker W.L., Van Tassell B.W. Effect of Intensive Blood Pressure Control in Patients with Type 2 Diabetes Mellitus Over 9 Years of Follow-Up: A Subgroup Analysis of High-Risk ACCORDION Trial Participants. Diabetes Obes Metab. 2018.
  71. Cayla G., Silvain J., O’Connor S.A., Collet J.P., Montalescot G. Current antiplatelet options for NSTE-ACS patients. QJM. 2012. 105(10): 935–948.
  72. Рекомендации по лечению стабильной ишемической болезни сердца. Российский кардиологический журнал. 2014. Т. 111. № 7. С. 7–79.
  73. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ ESC. Российский кардиологический журнал. 2014. Т. 107. № 3. С. 7–61.
  74. Spallone V., Ziegler D., Freeman R., Bernardi L., Frontoni S., Pop-Busui R., et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011. 27(7): 639–653.
  75. Szwed H., Sadowski Z., Pachocki R., Domzal-Bochenska M., Szymczak K., Szydlowski Z., et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999. 13(3): 217–222.
  76. Xu X., Zhang W., Zhou Y., Zhao Y., Liu Y., Shi D., et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. Clin Drug Investig. 2014. 34(4): 251–258.
  77. Shehata M. Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis. Cardiol Res. 2014. 5(2): 58–67.
  78. Yaman M., Arslan U., Gumrukcuoglu H.A., Sahin M., Simsek H., Akdag S. Effects of Trimetazidine on T Wave Alternans in Stable Coronary Artery Disease. Korean Circ J. 2016. 46(3): 343–349.
  79. Triggle C.R., Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014. 5(6): 245–268.
  80. Garber A.J., Abrahamson M.J., Barzilay J.I., Blonde L., Bloomgarden Z.T., Bush M.A., et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm-2016 Executive Summary. Endocr Pract. 2016. 22(1): 84–113.
  81. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009. 32(1): 193–203.
  82. Malin S.K., Nightingale J., Choi S.E., Chipkin S.R., Braun B. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obesity (Silver Spring). 2013. 21(1): 93–100.
  83. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998. 352(9131): 854–865.
  84. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359(15): 1577–1589.
  85. Kao J., Tobis J., McClelland R.L., Heaton M.R., Davis B.R., Holmes D.R., Jr., et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004. 93(11): 1347–1350, A1345.
  86. Floyd J.S., Wiggins K.L., Christiansen M., Dublin S., Longstreth W.T., Smith N.L., et al. Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. Pharmacoepidemiol Drug Saf. 2016. 25(2): 151–160.
  87. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016. 37(38): 2893–2962.
  88. Chang S.H., Wu L.S., Chiou M.J., Liu J.R., Yu K.H., Kuo C.F., et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014. 13: 123.
  89. Hemmingsen B., Schroll J.B., Wetterslev J., Gluud C., Vaag A., Sonne D.P., et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open. 2014. 2(3): E162–175.
  90. Maruthur N.M., Tseng E., Hutfless S., Wilson L.M., Suarez-Cuervo C., Berger Z., et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016. 164(11): 740–751.
  91. Evans J.M., Doney A.S., AlZadjali M.A., Ogston S.A., Petrie J.R., Morris A.D., et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010. 106(7): 1006–1010.
  92. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005. 28(10): 2345–2351.
  93. Вершинина Е.О., Репин А.Н. Контраст-индуцированная нефропатия при плановых эндоваскулярных вмешательствах на коронарных артериях. Сибирский медицинский журнал. 2016. Т. 31. № 3. С. 61–67.
  94. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015. 38(1): 140–149.
  95. Monami M., Genovese S., Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013. 15(10): 938–953.
  96. Comparative Safety and Efficacy of Glibenclamide in the Elderly. 18th Expert Committee on the Selection and Use of Essential Medicines. 2011.
  97. National Kidney F. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012. 60(5): 850–886.
  98. Ueba H., Kuroki M., Hashimoto S., Umemoto T., Yasu T., Ishikawa S.E., et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis. 2005. 183(1): 35–39.
  99. Azimova K., San Juan Z., Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014. 14(4): 616–632.
  100. Zou C., Hu H. Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk. Vasc Health Risk Manag. 2013. 9: 429–433.
  101. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005. 366(9493): 1279–1289.
  102. Gerich J.E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010. 27(2): 136–142.
  103. Wright E.M., Loo D.D., Hirayama B.A. Biology of human sodium glucose transporters. Physiol Rev. 2011. 91(2): 733–794.
  104. Hummel C.S., Lu C., Loo D.D., Hirayama B.A., Voss A.A., Wright E.M. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011. 300(1): C14–21.
  105. Rosenwasser R.F., Sultan S., Sutton D., Choksi R., Epstein B.J. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013. 6: 453–467.
  106. Grempler R., Thomas L., Eckhardt M., Himmelsbach F., Sauer A., Sharp D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012. 14(1): 83–90.
  107. Kovacs C.S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.J., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014. 16(2): 147–158.
  108. Chilton R., Tikkanen I., Cannon C.P., Crowe S., Woerle H.J., Broedl U.C., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015. 17(12): 1180–1193.
  109. Fitchett D., Zinman B., Wanner C., Lachin J.M., Hantel S., Salsali A., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016. 37(19): 1526–1534.
  110. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015. 373(22): 2117–2128.
  111. Salsali A., Kim G., Woerle H.J., Broedl U.C., Hantel S. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016. 18(10): 1034–1040.
  112. Neal B., Perkovic V., Mahaffey K.W., Fulcher G., Erondu N., Desai M., et al. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017. 19(7): 926–935.
  113. Doggrell S.A. Cardiovascular outcomes with canagliflozin - is it on the CANVAS? Expert Opin Pharmacother. 2018. 19(2): 163–166.
  114. Kosiborod M., Cavender M.A., Fu A.Z., Wilding J.P., Khunti K., Holl R.W., et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017. 136(3): 249–259.
  115. Kosiborod M., Lam C.S.P., Kohsaka S., Kim D.J., Karasik A., Shaw J., et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018. 71(23): 2628–2639.
  116. Raz I., Mosenzon O., Bonaca M.P., Cahn A., Kato E.T., Silverman M.G., et al. DECLARE- TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab. 2018. 20(5): 1102–1110.
  117. Goto H., Nomiyama T., Mita T., Yasunari E., Azuma K., Komiya K., et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun. 2011. 405(1): 79–84.
  118. Fadini G.P., Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab. 2010. 12(7): 570–583.
  119. Fadini G.P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011. 55(1–3): 10–16.
  120. Pfeffer M.A., Claggett B., Diaz R., Dickstein K., Gerstein H.C., Kober L.V., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015. 373(23): 2247–2257.
  121. Thompson A.M., Trujillo J.M. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015. 49(3): 351–359.
  122. Umpierrez G., Tofe Povedano S., Perez Manghi F., Shurzinske L., Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014. 37(8): 2168–2176.
  123. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. 375(4): 311–322.
  124. Davies M., Pieber T.R., Hartoft-Nielsen M.L., Hansen O.K.H., Jabbour S., Rosenstock J. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2017. 318(15): 1460–1470.
  125. Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jodar E., Leiter L.A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. 375(19): 1834–1844.
  126. Hjerpsted J.B., Flint A., Brooks A., Axelsen M.B., Kvist T., Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018. 20(3): 610–619.
  127. Geloneze B., de Lima-Junior J.C., Velloso L.A. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. Drugs. 2017. 77(5): 493–503.
  128. Blundell J., Finlayson G., Axelsen M., Flint A., Gibbons C., Kvist T., et al. Effects of once- weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017. 19(9): 1242–1251.
  129. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009. 374(9683): 39–47.
  130. Buse J.B., Nauck M., Forst T., Sheu W.H., Shenouda S.K., Heilmann C.R., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013. 381(9861): 117–124.
  131. Pratley R.E., Nauck M.A., Barnett A.H., Feinglos M.N., Ovalle F., Harman-Boehm I., et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014. 2(4): 289–297.
  132. Nauck M., Rizzo M., Johnson A., Bosch-Traberg H., Madsen J., Cariou B. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care. 2016. 39(9): 1501–1509.
  133. Dungan K.M., Povedano S.T., Forst T., Gonzalez J.G., Atisso C., Sealls W., et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014. 384(9951): 1349–1357.
  134. Ahmann A.J., Capehorn M., Charpentier G., Dotta F., Henkel E., Lingvay I., et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018. 41(2): 258–266.
  135. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015. 373(3): 232–242.
  136. Zannad F., Cannon C.P., Cushman W.C., Bakris G.L., Menon V., Perez A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015. 385(9982): 2067–2076.
  137. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013. 369(14): 1317–1326.
  138. Lorber D. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2014. 7: 169–183.
  139. Kansagara D., Fu R., Freeman M., Wolf F., Helfand M. Intensive insulin therapy in hospitalized patients: a systematic review. Ann Intern Med. 2011. 154(4): 268–282.
  140. American Diabetes A. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. Clin Diabetes. 2018. 36(1): 14–37.
  141. Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti F., et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016. 37(3): 267–315.
  142. Handelsman Y., Bloomgarden Z.T., Grunberger G., Umpierrez G., Zimmerman R.S., Bailey T.S., et al. American association of clinical endocrinologists and american college of endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015. 21 Suppl 1: 1–87.
  143. Summary of Revisions: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018. 41(Suppl 1): S4-S6.
  144. Handelsman Y., Henry R.R., Bloomgarden Z.T., Dagogo-Jack S., DeFronzo R.A., Einhorn D., et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Sglt-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016. 22(6): 753–762.
  145. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016. 37(27): 2129–2200.
  146. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update. Can J Diabetes. 2016. 40(3): 193–195.
  147. Avogaro A., Fadini G.P., Sesti G., Bonora E., Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016. 15(1): 111.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
СПИСОК ЛИТЕРАТУРЫ
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*